Pfizer is a US drug maker who has released late-stage human trails data of the Covid-19 vaccine that has been developed with German biotech Firm BioNTech. Pfizer and BioNtech has announced their mRNA-based vaccine candidate, BNT162B2, against SARS-CoV-2 has shown evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection.
According to the study based on the trials found split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy which is above 90%. The efficacy rate 90% is after the second dose. This consist 2-dose schedule and its given within the duration of 28 days.
“Today is a great day for science and humanity. The first set of results from our Phase3 COVID=19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” Said Dr.Albert Bourla, Pfizer Chairman and CEO in a statement released upon the results
“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a global collaborative effort,” Prof Ugur Sahin ,BioNTech ,Co-Founder and CEO in a statement released upon the results
